In summary, this trial demonstrated that coadministration of anti‐CD19 and anti‐CD20 CAR‐T cell therapy is safe and feasible with manageable toxicity even for those with bulk, MYC/BCL‐2 double expression, and CD5 positive DLBCL. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.